Lundbeck agrees to acquire Longboard Pharma for $2.6bn
Longboard’s lead candidate, bexicaserin, is a novel 5-HT2C agonist being developed for the treatment of seizures associated with developmental and epileptic encephalopathies (DEEs), currently in a Phase 3 DEEp SEA...
Effects of interstate armed conflicts on the pharmaceutical industry
Unveiling the impact of misinformation and disinformation in the pharmaceutical industry
The ripple effects of inflation on the pharmaceutical industry
Extreme weather events: The implications for the pharmaceutical industry